Director, Pipeline Commercialization Strategy (PCS) - Solid Tumor

AbbVie•North Chicago, IL

2d•$160,500 - $305,000

About The Position

This leadership position is accountable for delivering overall commercial strategy of the PCS oncology assets, by partnering closely with R&D, in-line commercial in US, international region, and countries, and other key stakeholders to plan for the commercialization of assets in the Oncology pipeline, thereby delivering successful global product launches within the portfolio in oncology.

Requirements

Bachelor’s degree; advanced degree (MBA, Ph.D, or MD) preferred
10-15+ years of experience in the pharmaceutical industry in progressive commercial leadership roles in marketing and/or sales. Recency of P&L ownership is preferred in US or other major markets
Successful launch experienced preferred
Managed care experience preferred
Oncology therapeutic experience preferred
Global experience preferred.
Demonstrated ability to influence and manage a complex set of internal and external stakeholders.
Strong strategic marketing skills including the ability to develop commercial strategies based on a thorough and structured approach, pared with a strong scientific/clinical understanding.
Strong financial and commercial acumen with thorough understanding of P&L drivers and the ability to develop appropriate investment and top-line sales forecasts that generate long-term value.
Strong executive presence and leadership skills are imperative as this leader will present to senior leaders on a regular basis and serve as a role model in the organization.
Demonstrated and consistent experience in successfully leading organizational change.
Outstanding partnering skills and the ability to lead a multi-disciplinary team and drive commercial decisions in a highly matrixed organization to accomplish business goals.
Proven track record of successful leadership, management and coaching of teams and individuals, and in having developed talent.

Responsibilities

Develop, champion and communicate vision and overall compelling strategy to all related stakeholder groups gaining commitment and support to guide portfolio prioritization, asset strategies and BD investments.
Understand market, key segment value drivers, growth opportunities, target product profiles, product positioning and revenue potential for multiple clinical-stage assets/indications within the franchise to drive winning portfolio value proposition plans and strong P&L investment thesis
(Co)-lead tumor disease are strategy teams for development of multiple assets within same tumor, when applicable – with enterprise and portfolio mindset
Defines and drives strategic value creation across lifecycle together with R&D and commercial cross-functional partners, integrating diverse internal and external perspectives
Partner with Global Medical Affairs, Pharma Development, and Commercial Cross functional leaders to develop scientific platforms and drive data generation to satisfy Global and Area requirements for target product labels and target product claims.
Identify new value generation for the franchise to unlock further opportunity. Drive innovative and novel ways to accelerate commercialization, and maximize value for patients and the company for the franchise
Drive prioritization of key leverage points in the treatment process and develop behavioral objectives for each stakeholder group to define commercial strategy for the assets and for the entire franchise
Effective and transparent risk, opportunity and issue management at strategic and operational levels across the franchise
Initiate geo-strategy and indication prioritization within the franchise in partnership with R&D, Commercial cross-functional leaders, and Affiliates on formulating optimal reimbursement and access strategies to fully realize value of multiple assets.
Exhibit clear and courageous leadership behavior and implements optimal program structures where appropriate to drive timely and effective decision making
Broaden AbbVie’s Oncology network and presence by building scientific, academic, KOL, payer, and patient advocacy relationships.